Lite Strategy, Inc., is a clinical-stage pharmaceutical company dedicated to the development of new and differentiated cancer therapies. The company builds its pipeline by acquiring promising cancer drugs and creates value in projects through clinical development, strategic partnerships, and outsourcing licensing or commercialization, as the case may be. Their pipeline of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor, a preclinical drug candidate.
